{
    "clinical_study": {
        "@rank": "159830", 
        "arm_group": [
            {
                "arm_group_label": "sequential therapy group", 
                "arm_group_type": "Active Comparator", 
                "description": "80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year"
            }, 
            {
                "arm_group_label": "Usual Therapy of atorvastatin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "20mg/d before and after PPCI for 1 year"
            }
        ], 
        "brief_summary": {
            "textblock": "Statins have been approved to benefit patients underwent percutaneous coronary intervention\n      (PCI). The current study is designed to evaluate the effectiveness and safety of Sequential\n      Therapy of Atorvastatin in patients with ST-elevated myocardial infarction and receive PCI\n      treatment."
        }, 
        "brief_title": "Sequential Therapy of Atorvastatin Improve Outcomes of ST-elevated Acute Myocardial Infarction", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Myocardial Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Infarction", 
                "Myocardial Infarction"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Sighed informed consent\n\n          -  Diagnosised as acute myocardial infarction\n\n          -  Time frame less than 12 hours since the occurance of chest pain\n\n          -  Aggred to receive sirolimus-eluted coronary stents\n\n          -  Patients willing to accepte follow-up\n\n        Exclusion Criteria:\n\n          -  Allegy to statins or with a history against statin therapy\n\n          -  Allegy to any products that will be used during PPCI\n\n          -  Disagreed to receive PPCI and other related therapy\n\n          -  Existing sever liver dysfuntion that statins can not be used according to the\n             guildlines\n\n          -  Sever kidney dysfunction (creatinine >3mg/dl or eGFR<30ml/min)\n\n          -  Sever left ventricular dysfunction (Killip grade 3)\n\n          -  Patients are currently taking medicine that may influence the use of statin\n\n          -  Patients with a history of alcohol abuse or durg abuse\n\n          -  Woman during pregnancy or lactation\n\n          -  Patients who has attended other clinical trials\n\n          -  Patients who has received PCI or CABG previously\n\n          -  Patients who can not agree to accept study protocol\n\n          -  Other conditions that may not sutible for the current study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01997294", 
            "org_study_id": "RJH20130115", 
            "secondary_id": "2011BAI11B05"
        }, 
        "intervention": {
            "arm_group_label": [
                "sequential therapy group", 
                "Usual Therapy of atorvastatin"
            ], 
            "description": "80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI", 
            "intervention_name": "Sequential therapy of atorvastatin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "sequential therapy", 
            "atorvastatin", 
            "acute myocardial infarction"
        ], 
        "lastchanged_date": "November 27, 2013", 
        "link": {
            "description": "website provided by CRO", 
            "url": "http://cdc.rocksh.cn/"
        }, 
        "location": {
            "contact": {
                "email": "rjchenxin@yahoo.com.cn", 
                "last_name": "Xin Chen, MD", 
                "phone": "+862164370045", 
                "phone_ext": "665380"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200025"
                }, 
                "name": "Ruijin Hospital, Dept. of Cardiology"
            }, 
            "investigator": {
                "last_name": "Ruiyan Zhang, MD.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Sequential Therapy of Atorvastatin Improving Tissue Reperfusion and Clinical Outcomes of ST-elevated Acute Myocardial Infarction Study\uff08The STRAIT Study\uff09", 
        "other_outcome": {
            "description": "Impairment of liver and kidney function\nOther adverse events related to statin use", 
            "measure": "Safty Endpoints", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "overall_contact": {
            "email": "Zhangruiyan@263.net", 
            "last_name": "Ruiyan Zhang, MD.", 
            "phone": "+8664370045", 
            "phone_ext": "665215"
        }, 
        "overall_contact_backup": {
            "email": "Gemini198306@163.com", 
            "last_name": "Zhengbin Zhu, MD.", 
            "phone": "+8664370045", 
            "phone_ext": "665380"
        }, 
        "overall_official": {
            "affiliation": "Institute of Cardiovascular Diseases, School of Medicine, Shanghai Jiao Tong University", 
            "last_name": "Weifeng Shen, MD. PhD.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "China: Ethics Committee", 
                "China: Ministry of Science and Technology"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cardiac Death (CD)\nNon-fatal re-inarction (CK-MB, cTNI or cTNT elevation again and over 3 times higher than up normal limit accompanied with syptoms or EKG indication)\nrevascularization driven by syptoms (CABG or re-PCI)", 
            "measure": "Major Adverse Events (MACE) Occourance Rate", 
            "safety_issue": "No", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01997294"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Jiao Tong University", 
            "investigator_full_name": "Zhang Qi, MD", 
            "investigator_title": "Visa Chief of Department of Cardiology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "TMP and TIMI grade chage after stents implantation; EKG ST reduction\nMACE ( same definition as primary endpoints)", 
            "measure": "Secondary Endpoints", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhang Qi, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}